The American journal of managed care
-
The rising prices of specialty drugs have prompted a debate about how medications are priced. With the average price of cancer drugs doubling in the last decade, the unsustainability of drug prices is especially concerning in oncology and hematology. The objective of this study was to compare the prices of monoclonal antibodies (mAbs) approved in the last 20 years by the FDA across disease states. ⋯ The annual price of mAb therapies is about $100,000 higher in oncology and hematology than in other disease states.